Axxam has several research programs in collaboration with a growing network of scientific partners, including several charities, to run state-of-the-art discovery programs and to develop novel technologies that improve the efficiency of the discovery process.
Axxam is a member of the following associations:
- Association of Italian Biotechnology Companies (Assobiotec/Federchimica)
- Association of Companies in the Province of Milan (Assolombarda)
- Society for Laboratory Automation and Screening (SLAS)
Axxam is proud to collaborate with many prominent life sciences companies in different fields of application.
Since our inception, we have been working with more than 100 customers, ranging from small biotechs to large pharma groups; from agri-chemical companies to cosmetics, nutraceuticals and flavor companies. We are a global operation with clients in the United States, Europe and Japan. Continuing to do business with us is the highest acknowledgment that our customers could give us.
Hit Discovery Constance GmbH provides high quality discovery research services to the Life Science industry and academic institutions as well as to the founding partners (LDC, CD3 and Axxam). The offering includes High Throughput Screening (“HTS”) using fully automated radiometric formats, automated High Content Screening (“HCS”), Biosafety level 2 (BSL2) HTS, and a REMP-based compound storage and handling facility which allows high quality storage and high throughput compound picking activities.
IMAX Discovery GmbH is a research driven company, creating innovation through the generation and development of novel and natural flavour compounds for the food and beverage industry. Using our strong technology platforms and expertise around taste receptors and natural products, IMAX Discovery GmbH generates proprietary product pipelines of natural product based novel taste modulators. IMAX Discovery GmbH is an equity joint venture between Axxam SpA and IMD Natural Solutions GmbH (INS). IMAX Discovery GmbH was founded in Dec 2010 and it is based in Dortmund, Germany.
Axxam and INS facilitate IMAX Discovery GmbH with its world leading Screening and Natural Product technology platforms and provide related services.
Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, and Pharmaceutical Sciences. The company maintains five global facilities with approximately 800 employees in Europe and the United States. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information about Aptuit.
“Aptuit and Axxam have established a collaboration relationship which allows both organisations to jointly offer to their clients comprehensive and integrated services from gene to high quality candidates and beyond, characterized by long industry expertise and heritage, with flexible and creative biotech spirit”.
The Centre for Drug Design and Discovery (CD3) is a technology transfer platform and investment fund focusing on the discovery and development of innovative medicines for all kinds of diseases. By providing the necessary drug discovery expertise and financial resources, CD3 ensures that biomedical research carried out by collaborating universities and small biotech companies is translated into promising compounds that can lead to new medicines, which can then further be developed by pharma or biotech industry. CD3 was set up at the end of 2006 by KU Leuven Research & Development and the European Investment Fund (EIF).
"CD3 is one of the founding partners of the Hit Discovery Constance GmbH (HDC - joint venture between Axxam, LDC and CD3) and is also collaborating with Axxam on a drug discovery program".
Cellectis bioresearch, subsidiary of Cellectis group, provides genome customization products and services to Life Science researchers. Based on in-field expertise and proprietary technologies, Cellectis bioresearch enables precise modifications of DNA sequences in a target genome, whether it is a cell line, a primary cell or stem cell. Cellectis bioresearch brings to the bench engineered cell lines and cellular models with the desired characteristics for optimal relevance and performance.
"From genes to functional assays, an extensive range of integrated Discovery services from Axxam and Cellectis bioresearch. Cellectis bioresearch offers comprehensive services based on its nuclease technologies (e.g. TALEN™) to deliver the most relevant cell models. Integrating Cellectis bioresearch‘s engineered cell lines, Axxam develops sensitive and robust functional assays".
Enamine is a leading provider of innovative screening libraries, building blocks, fragments, and comprehensive chemistry support in lead discovery. Enamine’s design and synthesis capabilities allow the addition of more than 250,000 new small molecular weight organic compounds to its catalogue each year. Enamine is committed to filling the gaps in the medchem toolkit of building blocks, which can be used in versatile lead discovery & optimization projects. Enamine offers collaborative expertise to exclusively design and supply libraries of new, potentially bioactive organic compounds. Enamine serves notably the pharmaceutical, agrochemical, cosmetic, nutritional and petrochemical industries.
"The relationship established with Axxam allows for a meaningful, cost effective path to value creation for the earliest features of drug discovery projects."
“IMD Natural Solutions (“INS”) aims to develop and commercialize groundbreaking ingredients - with a special focus on preserving agents - derived from "all" natural sources. The main target markets are in the Food & Beverages as well as the Personal Care industries. INS represents a one-stop service partner towards Natural Product research, development, production or supply. We have established longstanding professional experience in the Natural Product chemistry and biology field and operate a world leading Natural Product technology platform, covering the whole array of relevant areas, such as NP-chemistry, analytics, fermentation/extraction and production.
“INS facilitates IMAX Discovery GmbH, the joint venture targeting the identification of innovative taste modulating ingredients formed together with Axxam, with its world leading Natural Product technology platform and provides related services.”
The Lead Discovery Center (LDC), a translational drug discovery company, aims to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. LDC takes on promising early-stage projects from academia and - in close collaboration with its partners from academia and industry - transforms them into innovative pharmaceutical leads with proof-of-concept in animal.
LDC sustains a preferred partnership with the Max Planck Society and has formed alliances with AstraZeneca, Bayer and Merck Serono as well as leading academic drug discovery centers around the globe.
“We value Axxam’s expertise & strong track record in the screening service business - both as a partner in our joint venture HDC GmbH as well as in our collaborative drug discovery projects”.